FDA Adverse Event Injury Summary report: N

TOTAL ASR ACET IMP SIZE 58

MDR report key: 3191611 · Received June 26, 2013

Report

Report Number
1818910-2013-19950
Event Type
Injury
Date Received
June 26, 2013
Date of Event
December 21, 2012
Report Date
August 29, 2014
Manufacturer
DEPUY INTERNATIONAL LTD.
Product Code
KWA
Removal / Correction Number
Z-1749/1816-2011
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
US
Reporter Occupation
PATIENT

Narratives

Additional Manufacturer Narrative · 1

NO 510(K) NUMBER PROVIDED BECAUSE THIS IMPLANT IS SOLD INTERNATIONALLY WITH DIFFERENT INDICATIONS FOR USE; IT IS CURRENTLY SOLD IN THE US UNDER A DIFFERENT PART NUMBER. THE CORRECTION/REMOVAL REPORTING NUMBER LISTED APPLIES TO THE CORRESPONDING PRODUCT CODE SOLD DOMESTICALLY. THE ASR PLATFORM WAS VOLUNTARILY RECALLED FROM THE MARKET IN AUGUST 2010, AND THE ASR PRODUCT CODES ARE NOW CONSIDERED INACTIVE. FURTHER INVESTIGATION OF THIS INDIVIDUAL INCIDENT WILL NOT BE UNDERTAKEN, AS THERE IS AN ONGOING INVESTIGATION REGARDING THE ROOT CAUSE(S) AND/OR CORRECTIVE ACTIONS. REF. (B)(4). DEPUY CONSIDERS THE INVESTIGATION CLOSED AT THIS TIME. SHOULD THE PRODUCT AND/OR ADDITIONAL INFORMATION BE RECEIVED, THE INVESTIGATION WILL BE RE-OPENED.

Additional Manufacturer Narrative · 1

IF INFORMATION IS OBTAINED THAT WAS NOT AVAILABLE FOR THE INITIAL MEDWATCH, A FOLLOW-UP MEDWATCH WILL BE FILED AS APPROPRIATE. DEPUY STILL CONSIDERS THIS CASE CLOSED TO CAPA.

Description of Event or Problem · 1

ASR REVISION, ASR XL - RIGHT, REASON(S) FOR REVISION: ALVAL / SOFT TISSUE REACTION.

Description of Event or Problem · 1

ASR REVISION, ASR XL - RIGHT, REASON(S) FOR REVISION: ALVAL / SOFT TISSUE REACTION. REOPENED TO CORRECT COUNTRY. UPDATE 29 AUG 2014 - AMENDED DOI TO (B)(6) 2005. UPDATED COMMON NAME AND DATE OF MANUFACTURE FOR EACH PRODUCT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
290333 TOTAL ASR ACET IMP SIZE 58 HIP ACETABULAR CUP KWA DEPUY INTERNATIONAL LTD. 1870311

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention